Nieuws en video's - GILEAD SCIENCES INC.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2025 financial results and guidance will be released on Thursday, April 24, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s first quarter 2025 financial results and provide a business update. A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year. About Gilead Sciences Gilead...

NORTHAMPTON, MA / ACCESS Newswire / April 10, 2025 / At Gilead, putting people first is central to all we do. That's why we're proud to be recognized as a responsible company by patient advocacy groups representing more than 70 countries. In a new report from UK-based PatientView, we were ranked "best" at ESG by patient groups who work with us. About Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative...

NORTHAMPTON, MA / ACCESS Newswire / April 8, 2025 / In 2019, Somchai, a Thai native, was 21 years old and faced a double threat to his long-term health and wellbeing. He was living with hepatitis B (HBV) and with advanced HIV. "Since both viruses are bloodborne and transmitted in similar ways, coinfections can be quite common," says Dr. Anchalee Avihingsanon, the lead clinical researcher at the Thai Red Cross AIDS and Infectious Diseases Research Centre where Somchai sought treatment. Anchalee...

NORTHAMPTON, MA / ACCESS Newswire / April 3, 2025 / We're focused on driving innovation in virology, oncology and immunology - and that includes investing in world-class science to change the way cancer is treated. In the latest episode of The Centrifuge Sessions, hear from Samuel Haile, Ph.D. , Director of Cell Biology at Kite Pharma , on how we're working to deliver cell therapies that offer new hope for patients. Originally published by Gilead Sciences About Gilead Sciences Gilead Sciences,...

NORTHAMPTON, MA / ACCESS Newswire / April 1, 2025 / In 2006, Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground around the globe and existing therapies were limited. He was 12 years into his virology research career at Gilead and the first daily single tablet regimen for HIV treatment was still awaiting approval. Treatment options for people living with HIV at the time were a raft of daily medications that often carried...

actualités #cac40 #bourse #economie #trading #analysetechnique #marchésfinanciers #shorts #short....

NORTHAMPTON, MA / ACCESS Newswire / March 25, 2025 / HIV infection and lung cancer have little in common from a disease perspective, but the stigma that surrounds both can negatively impact patients and their treatment. Now lessons learned from the HIV epidemic are helping people living with lung cancer and their loved ones. During the first years of the HIV epidemic, some of the initial stigmatizing beliefs were that the virus only impacted men who have sex with men and that it was possible to...

actualités #cac40 #bourse #economie #trading #analysetechnique #marchésfinanciers #shorts #short....

actualités #cac40 #bourse #economie #trading #analysetechnique #marchésfinanciers #shorts #short....

Jean-François Chauffeté, Fondateur de Phocus1 présente son fonds d'investissement alternatif sur les devises. Avec un ......

NORTHAMPTON, MA / ACCESS Newswire / March 18, 2025 / We're proud to once again be ranked in the top five of Americas Most Just companies in biopharma. The honor reflects our ongoing commitment to operate responsibly and empower our employees to help create a healthier world for all. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care...

NORTHAMPTON, MA / ACCESS Newswire / March 14, 2025 / In recognition of Women's History Month, our Identity + Innovation spotlight features Devi SenGupta . Hear how Devi's background has shaped her approach to developing new medicines and to bringing Gilead closer to a cure for HIV. Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference on Retroviruses and Opportunistic Infections (CROI 2025). The new findings reflect a transformative portfolio and a rapidly advancing forward-looking pipeline focused on expanding choices and enhancing outcomes for those with HIV, while continuing to reach towards a cure. “Gilead is fueling the...

Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention as pre-exposure prophylaxis (PrEP). The data were presented during an oral abstract session at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) and were also published today in The Lancet . Data will support the...

Debiopharm ( www.debiopharm.com ), société biopharmaceutique indépendante basée en Suisse dont la vocation est de développer les traitements de référence de demain afin de guérir le cancer et les maladies infectieuses, et MEDSIR ( www.medsir.org ), une organisation de recherche internationale innovante en oncologie clinique basée en Espagne et aux États-Unis, ont annoncé aujourd’hui qu’une première patiente a été traitée dans le cadre de l’étude clinique WIN-B évaluant la...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated for parallel accelerated review the company’s Marketing Authorization Application (MAA) and EU-Medicines for all (EU-M4all) application for lenacapavir—the company’s twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP). Based on the assessment of EMA’s Committee for Medicinal Products for Human Use (CHMP) that twice-yearly...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA. Seladelpar (an orphan designated product) is now approved and will provide an important treatment option for people living with the rare...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: TD Cowen Annual Health Care Conference on Tuesday, March 4 at 11:10 AM Eastern Time Leerink Partners Global Healthcare Conference on Tuesday, March 11 at 10:40 AM Eastern Time The live webcasts can be accessed at the company’s investors page at investors.gilead.com . The replays will be available for at least 30 days following the presentation. About Gilead Sciences...

NORTHAMPTON, MA / ACCESS Newswire / February 19, 2025 / Take a spin through the latest in Gilead's science and innovation in our new series, The Centrifuge Sessions. Today we sit down with D. Barry Crittenden , Executive Director of Clinical Development, to discuss how Gilead is helping make an impact for people living with primary biliary cholangitis (PBC), a rare autoimmune disease that affects the liver. Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir—the company’s twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP). The FDA will review the applications under priority review and has assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 19, 2025. Acceptance of the NDAs follows receipt of...